-- Torr Metals (TMET.V) 周三宣布，计划在其位于不列颠哥伦比亚省的 Kolos 铜金矿项目启动二期钻探计划。此前，该项目 2025 年的钻探工作已在该矿区发现了 68 个铜矿化带。 该公司表示，二期钻探将重点关注 Bertha North 靶区，以测试“中高电阻率地球物理异常”。 该公司称，现场工作人员已进驻现场，目前正在进行勘测取样、无人机磁测和激发极化 (IP) 勘测，以进一步确定目标区域，为计划于 2026 年第二季度进行的钻探工作做好准备。 首席执行官 Malcolm Dorsey 表示：“二期钻探旨在直接测试该靶区，这标志着从确定矿体系统到确定其潜在矿源的重要一步。与此同时，目前的地球物理勘探工作重点是确定一期钻探区域东北部以及 Kova 矿区是否存在类似的矿源特征，我们将继续扩大和优化高优先级靶区。” 该公司股票在多伦多证券交易所创业板最新报收上涨0.005美元，至0.105美元。
Related Articles
Asia
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
$ASX:ONE
Asia
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
$ASX:PAR
Asia
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.
$SHA:600703